1. Home
  2. YRD vs EDIT Comparison

YRD vs EDIT Comparison

Compare YRD & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yiren Digital Ltd.

YRD

Yiren Digital Ltd.

N/A

Current Price

$4.31

Market Cap

407.8M

Sector

Finance

ML Signal

N/A

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

N/A

Current Price

$2.38

Market Cap

233.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
YRD
EDIT
Founded
2012
2013
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
407.8M
233.3M
IPO Year
2015
2016

Fundamental Metrics

Financial Performance
Metric
YRD
EDIT
Price
$4.31
$2.38
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
$4.13
AVG Volume (30 Days)
77.2K
1.6M
Earning Date
11-25-2025
11-10-2025
Dividend Yield
10.16%
N/A
EPS Growth
N/A
N/A
EPS
2.03
N/A
Revenue
$872,820,262.00
$46,383,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.14
N/A
Revenue Growth
10.41
N/A
52 Week Low
$4.15
$0.91
52 Week High
$8.74
$4.54

Technical Indicators

Market Signals
Indicator
YRD
EDIT
Relative Strength Index (RSI) 32.67 41.82
Support Level $4.27 $2.40
Resistance Level $4.44 $2.70
Average True Range (ATR) 0.15 0.18
MACD 0.03 0.04
Stochastic Oscillator 20.84 45.90

Price Performance

Historical Comparison
YRD
EDIT

About YRD Yiren Digital Ltd.

Yiren Digital Ltd is an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. Its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: